Equities
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)1,487.00
  • Today's Change-26.50 / -1.75%
  • Shares traded8.17m
  • 1 Year change-33.59%
  • Beta0.7222
Data delayed at least 20 minutes, as of May 17 2024 07:00 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Cash flow Back to Overview

In millions of JPY
(except for per share items)
Fiscal data as of Mar 31 2024202420232022
OPERATIONS
Net income24,969132,361156,886
Depreciation/depletion157,840105,73879,684
Non-Cash items79,48085,16773,650
Cash taxes paid, supplemental38,11269,47942,093
Cash interest paid, supplemental------
Changes in working capital(89813)4,501(52777)
Total cash from operations172,476327,767257,443
INVESTING
Capital expenditures(82497)(88541)(76448)
Other investing and cash flow items, total(763305)4,04114,035
Total cash from investing(845802)(84500)(62413)
FINANCING
Financing cash flow items(16539)(3217)(2530)
Total cash dividends paid(116653)(100355)(85236)
Issuance (retirement) of stock, net(10735)(60556)(50717)
Issuance (retirement) of debt, net757,987(31495)(77815)
Total cash from financing614,060(195623)(216298)
NET CHANGE IN CASH
Foreign exchange effects18,11313,21011,125
Net change in cash(41153)60,854(10143)
Net cash-begin balance/reserved for future use376,840315,986326,128
Net cash-end balance/reserved for future use335,687376,840315,986
SUPPLEMENTAL INCOME
Depreciation, supplemental157,840105,73879,684
Cash interest paid, supplemental------
Cash taxes paid, supplemental38,11269,47942,093
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.